Lucentis vs PDT: which is more cost-effective?

Article

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration, from the December 2008 issue of Clinical Therapeutics.

Please click here to read the abstract.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.